T2 Biosystems Reports Granting of Inducement Awards
April 04 2018 - 4:05PM
T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the
development and commercialization of innovative medical diagnostic
products for critical unmet needs in healthcare, announced today
that on April 2, 2018 it issued inducement awards to five new
employees.
These awards were made under T2 Biosystems’ Inducement Award
Plan (the "Inducement Plan"), which was adopted by the company’s
Board of Directors on March 1, 2018 and provides for the granting
of equity awards to new employees of T2 Biosystems. The inducement
awards consist of options to purchase 49,000 shares of T2
Biosystems common stock and have a ten-year term. The exercise
price of the options is $6.32, which was the per-share closing
price of T2 Biosystems common stock on the Nasdaq Capital Market on
April 2, 2018. The options vest over a four-year period, with 25%
vesting on the first anniversary of the employee’s date of hire and
the remainder vesting in equal monthly installments over the three
years thereafter. The award was approved by the independent
compensation committee of T2 Biosystems’ board of directors and was
granted as an inducement material to the new employee entering into
employment with T2 Biosystems in accordance with Nasdaq Marketplace
Rule 5635(c)(4).
About T2 Biosystems T2 Biosystems, an
emerging leader in the development and commercialization of
innovative medical diagnostic products for critical unmet needs in
healthcare, improves patient care and reduces the cost of
healthcare by helping clinicians effectively treat patients faster
than ever before. T2 Biosystems’ products include the
T2Dx® Instrument, T2Candida® Panel, and the T2Bacteria®
Panel and are powered by the proprietary T2 Magnetic Resonance
technology, or T2MR®. T2Bacteria Panel is commercially
available in Europe and other countries that accept the
CE Mark and is available for research use only in the U.S. For more
information, please
visit www.t2biosystems.com.
T2 Biosystems Media Contact: Amy Phillips,
Feinstein Kean
Healthcare amy.phillips@fkhealth.com 412-327-9499
T2 Biosystems Investor Contact: Chris
Brinzey, Westwicke Partners
chris.brinzey@westwicke.com 339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024